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Abstract 
ABSTRACT 
In classic APL (acute promyelocytic leukemia), the 
central leukemia-initiating event is the fusion 
between the promyelocytic leukemia (PML) and the 
retinoic acid receptor alpha (RARA) gene, that arise 
as a result of t(15;17)(q22;q21) chromosomal 
translocation. In variant forms of APL, RARA gene 
have other translocation partners than PML resulting 
in various molecular characteristics and sensitivities 
to all-trans-retinoic acid (ATRA) therapy. The 
variant t(3;17)(q26;q21) translocation, in which 
RARA is fused to TBL1XR1 (transducin beta like 1 
X-linked receptor 1, TBLR1) is a rare anomaly, 
observed only in sporadic cases. 
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Clinics and pathology 
Disease 
Acute promyelocytic leukemia (APL; FAB type M3) 
Epidemiology 
4 cases to date, 3 male and 1 female patients; ages at 
diagnosis was documented in 2 cases: 27 and 63 
years (Macedo et al., 2005; Chen et al., 2014). 
Clinics 
In one patient, data were available: bone marrow 
cells revealed hypercellularity with 83% 
hypergranular promyelocytes lacking Auer rods. 
Immunophenotyping analysis by flow cytometry 
was positive for myeloperoxidase, CD13, CD9 with 
partially expressed CD117, CD15, CD33, and 
CD64; CD34 and HLA-DR were negative (Chen et 
al., 2014). 
Prognosis 
The one patient well described in Chenn et al., 2014 
(63-year-old male patient) received induction 
therapy with ATRA, cytarabine, and mitoxantrone 
but failed to achieve complete remission (58% 
promyelocytes on day 32). Therapy with ATRA 
should be suspended on day 24 because of severe 
pulmonary infection. He was subsequently treated 
with arsenic trioxide and chemotherapy resulting in 
complete remission, but 10 months after diagnosis he 
relapsed with 81% of promyelocytes in bone marrow 
and died 1 month later (Chen et al., 2014). The 
female patient reported by Chen et al., 2014 was 
initially treated with ATRA and daunorubicin and 
achieved CR on day 36. However, in addition to the 
t(3;17)(q21;q25) TBL1XR1/RARA, a 
t(15;17)(q22;q12) PML/RARA transcript was also 
detected in this patient. In Machedo et al., 2005, the 
rearrangement t(3;17)(q26.3;q12) was accompanied 
with a poor outcome. Due to the limited data 
available regarding patient outcomes, the efficiency 
of ATRA on APL patients with TBLR1/RARA is 
unclear. 
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Cytogenetics 
Cytogenetics morphological 
Variable breakpoints on 3q and 17q, described as: 
t(3;17)(q26;q21), t(3;17)(q27;q22), t(3;17)(q21;q25) 
(Chen et al., 2014) (Author's note: the latter may be 
t(3;17)(q25;q21) ?) and as a t(3;17)(q26;q12) in a 
patient with unknown gene involved at 3q26 
(Macedo et al., 2005). 
Additional anomalies 
Part of complex karyotypes in all the 4 patients; 
recurrent abnormalities were: del(6)q), -7, del(7q) 
and in 1 patient t(15;17)(q22;q12) with PML/RARA 
fusion as above mentioned (Chen et al., 2014). 
Genes involved and 
proteins 
TBL1XR1 (transducin beta like 1 X-
linked receptor 1) 
Location 
3q26.32 
DNA/RNA 
Approximately 200 kb of genomic DNA, containing 
18 exons; member of the WD40 repeat-containing 
gene family and shares sequence similarity with 
transducin (beta)-like 1X-linked (TBL1X). 
Protein 
514 amino acids; contains lissencephaly type-1-like 
homology motif (LisH domain) in its N-terminal 
region, F-box-like domain, and 8 WD-40 repeats in 
its C-terminal region; an integral subunit of the 
NCOR1 (NCoR, nuclear receptor corepressor) and 
NCOR2 (SMRT, silencing mediator of retinoic acid 
and thyroid hormone receptors) repressor complexes 
that interact with nuclear receptors and repress 
transcription; required for transcriptional activation 
by a variety of transcription factors (Li et al., 2014). 
Germinal mutations 
Heterozygous missense mutation of TBL1XR1 is 
associated with autosomal dominant Pierpont 
syndrome; deletions and mutations in this gene have 
been implicated in autism spectrum disorders and it 
is suggested that TBL1XR1 haploinsufficiency may 
be a cause of intellectual disability with 
dysmorphism (Heinen et al., 2016). 
Somatic mutations 
TBL1XR1 mutations and recurrent translocations 
involving this gene have been observed in lymphatic 
malignancies, including diffuse large B-cell 
lymphoma, primary central nervous system 
lymphomas, acute lymphoblastic leukaemia and 
Sézary syndrome (Heinen et al., 2016). 
RARA (Retinoic acid receptor, alpha) 
Location 
17q21.2 
Protein 
Nuclear retinoic acid receptor, implicated in 
regulation of development, differentiation, 
apoptosis, granulopoeisis, and transcription.  
Retinoic acid receptor alpha belongs to the nuclear 
hormone receptor family composed of a modulating 
N-terminal domain, a nuclear receptor DNA-binding 
domain and a C-terminal ligand-binding domain. 
RARA can be combined with retinoid X receptor 
alpha to bind the retinoic acid responsive element 
composed of tandem 5'-AGGTCA-3' sites; mediates 
retinoic acid-induced granulopoiesis and regulates 
transcription in a ligand-dependent manner in 
various biological processes. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
5'-TBLR1-3' RARA 
Transcript 
In-frame fusion transcript; TBLR1 exon 5 is fused to 
exon 3 of RARA 
Fusion protein 
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Schematic representation of TBLR1, RARA and TBLR1/RARA proteins. Abbreviations: LisH (lissencephaly 
type-1-like homology motif); DBD; DNA-binding domain; (LBD), ligand-binding domain (Adopted from Chen 
et al., 2014). 
Description 
Predicted to encode a 545 amino acids (aa) fusion 
protein, containing a LisH domain (6-32 aa) in the 
TBLR1 portion and a DNA-binding domain (DBD; 
166-250 aa) and a ligand-binding domain (LBD; 
270-500 aa) in the RARA portion (B through F 
domains of RARA) (Chen et al., 2014; Heinen et al., 
2016). 
Oncogenesis 
The common feature of RARA fusion proteins is the 
ability to self-associate, forming homodimers. The 
TBL1XR1/RARA fusion protein is predominantly 
localized in the nucleus and self-associate into 
homodimers through its LisH domain and associate 
with retinoid X receptor alpha into heterodimers. 
The multimerization of the chimeric protein may be 
a key factor in interfering with normal signaling 
leading to diminished transcriptional activity. 
References 
Chen Y, Li S, Zhou C, Li C, Ru K, Rao Q, Xing H, Tian Z, 
Tang K, Mi Y, Wang B, Wang M, Wang J. TBLR1 fuses to 
retinoid acid receptor α in a variant t(3;17)(q26;q21) 
translocation of acute promyelocytic leukemia. Blood. 2014 
Aug 7;124(6):936-45 
Heinen CA, Jongejan A, Watson PJ, Redeker B, Boelen A, 
Boudzovitch-Surovtseva O, Forzano F, Hordijk R, Kelley R, 
Olney AH, Pierpont ME, Schaefer GB, Stewart F, van 
Trotsenburg AS, Fliers E, Schwabe JW, Hennekam RC. A 
specific mutation in TBL1XR1 causes Pierpont syndrome. J 
Med Genet. 2016 May;53(5):330-7 
Li JY, Daniels G, Wang J, Zhang X. TBL1XR1 in 
physiological and pathological states. Am J Clin Exp Urol. 
2015;3(1):13-23 
Macedo Silva ML, Land M, Heller A, Abdelhay E, do Socorro 
Pombo-de-Oliveira M, Ribeiro R, Alves G, Lerner D, Liehr 
T. New rearrangement t(3;17)(q26.3;q12) in an AML patient 
with a poor outcome. Oncol Rep. 2005 Sep;14(3):663-6 
This article should be referenced as such: 
Zamecnikova At(3;17)(q26;q12-21) 
TBL1XR1/RARA. Atlas Genet Cytogenet Oncol 
Haematol. 2018; 22(4) :167-169. 
